Analysts forecast that IMV Inc. (NASDAQ:IMV) will announce earnings per share (EPS) of ($0.13) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for IMV’s earnings, with estimates ranging from ($0.14) to ($0.11). IMV reported earnings of ($0.11) per share in the same quarter last year, which indicates a negative year over year growth rate of 18.2%. The business is expected to issue its next quarterly earnings report on Wednesday, March 16th.
According to Zacks, analysts expect that IMV will report full year earnings of ($0.38) per share for the current fiscal year, with EPS estimates ranging from ($0.46) to ($0.27). For the next financial year, analysts anticipate that the firm will post earnings of ($0.44) per share, with EPS estimates ranging from ($0.65) to ($0.23). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow IMV.
IMV (NASDAQ:IMV) last announced its earnings results on Thursday, November 11th. The company reported ($0.13) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.13). The company had revenue of $0.04 million for the quarter. IMV had a negative return on equity of 118.77% and a negative net margin of 14,569.68%. During the same period in the prior year, the business posted ($0.10) earnings per share.
IMV stock opened at $1.22 on Friday. The company has a market capitalization of $100.25 million, a PE ratio of -2.71 and a beta of 1.40. The company has a 50 day moving average price of $1.42 and a 200-day moving average price of $1.61. The company has a debt-to-equity ratio of 0.24, a quick ratio of 5.20 and a current ratio of 5.20. IMV has a fifty-two week low of $1.19 and a fifty-two week high of $4.60.
Large investors have recently bought and sold shares of the business. Virtu Financial LLC bought a new stake in shares of IMV during the 2nd quarter valued at $45,000. Geode Capital Management LLC increased its position in IMV by 44.7% in the third quarter. Geode Capital Management LLC now owns 38,325 shares of the company’s stock worth $63,000 after buying an additional 11,833 shares during the last quarter. Millennium Management LLC purchased a new position in IMV during the second quarter worth about $69,000. Renaissance Technologies LLC bought a new stake in shares of IMV in the 2nd quarter valued at about $70,000. Finally, JPMorgan Chase & Co. purchased a new stake in shares of IMV in the 2nd quarter worth approximately $88,000. 12.52% of the stock is currently owned by hedge funds and other institutional investors.
IMV, Inc is a clinical-stage biopharmaceutical company that engages in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company leverages its delivery platform (DPX) that programs immune cells directly within the human body to produce robust and sustained target killing capabilities.
Featured Story: What are high-yield dividend stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.